CoImmune, Inc., a US-Based Clinical-Stage Biotech, Completes Merger with Formula Pharmaceuticals, Inc.

DURHAM, N.C. , April 30 (Korea Bizwire) — CoImmune, Inc. today announced that it has successfully completed the merger with Formula Pharmaceuticals, Inc., bringing together two therapeutic immuno-oncology platforms. Formula Pharmaceuticals merged into CoImmune with CoImmune as the surviving company. CoImmune will continue to focus on running a Phase 2b trial for lead asset, CMN-001, [...]

CoImmune Inc., a US-based Clinical-stage Biotech, and Formula Pharmaceutical Inc. Agree to Merge in an All-stock Transaction

DURHAM, N.C., Jan. 15 (Korea Bizwire) — CoImmune, Inc. and Formula Pharmaceuticals, Inc. announced today the merger between the two companies, bringing together two therapeutic immuno-oncology platforms. Upon completion of the merger of Formula Pharmaceuticals into CoImmune, bringing forth access to all of Formula Pharmaceuticals’ tangible and intangible assets, the merged company will continue to [...]